Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Aug 22;10(10):1807–1817. doi: 10.1158/1535-7163.MCT-11-0362

Figure 2. Identification of NSC 47147 as a FADD-kinase inhibitor.

Figure 2

(A) A549-FKR cells were treated with NSC 47147 and SP600125 for 6 hours and CKI7 for 1 hour, at the indicated concentrations followed by bioluminescent measurement. NSC 47147 blocks phosphorylation of FADD with greater potency than FADD-kinase inhibitors, SP600125 and CKI7. (B) A549-FKR cells were treated as described for FKR reporter assay and lysates analyzed with specific antibodies by western blot. Treatment with FADD-kinase inhibitors, CKI7 and SP600125 show dose dependent decrease in phosphorylated FADD protein that correlates with FKR activity. Total and phosphorylated β-catenin and cJun, respective targets of CKI7 and SP600125, have been shown for comparison. (C) A549 and Jurkat cells were treated for 6 hours with NSC 47147. Western blot analysis reveals NSC 47147 leads to a decrease in pFADD and p-β-catenin levels.